TELIX PHARMACEUTICAL ORDINARY (TLX) Short Interest
TELIX PHARMACEUTICAL ORDINARY (ASX:TLX) had 11.88% of shares reported as short positions as of 16 July 2026, representing 40,309,344 shares. TELIX PHARMACEUTICAL ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Short interest history & FAQ
Latest TLX news
All news- Down 9%: Is the rebound over for Telix shares?
motleyfool
- Why Are Telix Pharmaceuticals (ASX:TLX) and Other Insider-Owned Growth Stocks in Focus?
kalkine
- Telix Pharmaceuticals (ASX:TLX) Move That Could Reshape Its Growth Story
kalkine
- Telix Pharmaceuticals (ASX:TLX) Pulls Back: Is the Healthcare Growth Trade Cooling? - Kalkine
googlenews
- Telix Pharmaceuticals (ASX:TLX): Why Did This Radiopharmaceutical Company's Shares Come Under Pressure? - Kalkine
googlenews
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector